<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Alto Neuroscience, Inc. — News on 6ix</title>
<link>https://6ix.com/company/alto-neuroscience-inc</link>
<description>Latest news and press releases for Alto Neuroscience, Inc. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 04 May 2026 12:03:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/alto-neuroscience-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835467578dffbe2df0e2fe5.webp</url>
<title>Alto Neuroscience, Inc.</title>
<link>https://6ix.com/company/alto-neuroscience-inc</link>
</image>
<item>
<title>Alto Neuroscience Presents Phase 2a Data for ALTO-207 in Major Depressive Disorder at SOBP Annual Meeting</title>
<link>https://6ix.com/company/alto-neuroscience-inc/news/alto-neuroscience-presents-phase-2a-data-for-alto-207-in-major-depressive-disorder-at-sobp-annual-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/alto-neuroscience-inc/news/alto-neuroscience-presents-phase-2a-data-for-alto-207-in-major-depressive-disorder-at-sobp-annual-meeting</guid>
<pubDate>Mon, 04 May 2026 12:03:00 GMT</pubDate>
<description>MOUNTAIN VIEW, Calif., May 04, 2026--Alto Neuroscience, Inc. (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on precision medicines for neuropsychiatric disorders, today announced the presentation of data from a randomized, single-blind, placebo-controlled Phase 2a trial of ALTO-207 (formerly CTC-501) in patients with Major Depressive Disorder (MDD). The data were presented in a poster session at the 2026 Annual Meeting of the Society of Biological Psychiatry (SOBP).</description>
</item>
<item>
<title>Alto Neuroscience Initiates Phase 2b Trial of ALTO-207 in Treatment-Resistant Depression</title>
<link>https://6ix.com/company/alto-neuroscience-inc/news/alto-neuroscience-initiates-phase-2b-trial-of-alto-207-in-treatment-resistant-depression</link>
<guid isPermaLink="true">https://6ix.com/company/alto-neuroscience-inc/news/alto-neuroscience-initiates-phase-2b-trial-of-alto-207-in-treatment-resistant-depression</guid>
<pubDate>Tue, 21 Apr 2026 12:03:00 GMT</pubDate>
<description>MOUNTAIN VIEW, Calif., April 21, 2026--Alto Neuroscience, Inc. (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on precision medicines for neuropsychiatric disorders, today announced the initiation of a Phase 2b randomized, placebo-controlled trial of ALTO-207 in treatment-resistant depression (TRD), a program designed to replicate the strongly positive PAX-D study results and support a streamlined path to registration. TRD is estimated to affect up to 7 million adults in the Uni</description>
</item>
<item>
<title>Alto Neuroscience Reports Topline Data from Phase 2 Proof-of-Concept Study of ALTO-101 and Highlights Pipeline Advancements</title>
<link>https://6ix.com/company/alto-neuroscience-inc/news/alto-neuroscience-reports-topline-data-from-phase-2-proof-of-concept-study-of-alto-101-and-highlights-pipeline-advancements-2</link>
<guid isPermaLink="true">https://6ix.com/company/alto-neuroscience-inc/news/alto-neuroscience-reports-topline-data-from-phase-2-proof-of-concept-study-of-alto-101-and-highlights-pipeline-advancements-2</guid>
<pubDate>Wed, 01 Apr 2026 20:30:00 GMT</pubDate>
<description>MOUNTAIN VIEW, Calif., April 01, 2026--Alto Neuroscience, Inc. (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on precision medicines for neuropsychiatric disorders, today announced topline data from its Phase 2 proof-of-concept (POC) clinical trial evaluating ALTO-101 for the treatment of cognitive impairment associated with schizophrenia (CIAS), and provided an update on the Company's pipeline and prioritization.</description>
</item>
<item>
<title>NYSE Content Update: Alto Neuroscience Raises $120 Million to Fund Development of ALTO-207</title>
<link>https://6ix.com/company/alto-neuroscience-inc/news/nyse-content-update-alto-neuroscience-raises-dollar120-million-to-fund-development-of-alto-207</link>
<guid isPermaLink="true">https://6ix.com/company/alto-neuroscience-inc/news/nyse-content-update-alto-neuroscience-raises-dollar120-million-to-fund-development-of-alto-207</guid>
<pubDate>Mon, 23 Mar 2026 12:55:00 GMT</pubDate>
<description>The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins.</description>
</item>
<item>
<title>Alto Neuroscience Announces $120 Million Private Placement Financing</title>
<link>https://6ix.com/company/alto-neuroscience-inc/news/alto-neuroscience-announces-dollar120-million-private-placement-financing</link>
<guid isPermaLink="true">https://6ix.com/company/alto-neuroscience-inc/news/alto-neuroscience-announces-dollar120-million-private-placement-financing</guid>
<pubDate>Mon, 16 Mar 2026 11:03:00 GMT</pubDate>
<description>MOUNTAIN VIEW, Calif., March 16, 2026--Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, announced today that it has entered into a securities purchase agreement with institutional and accredited investors to sell securities in a private placement financing (the "PIPE") for gross proceeds of approximately $120 million, before deducting offering expenses. The financing i</description>
</item>
<item>
<title>Alto Neuroscience Reports Full Year 2025 Financial Results and Recent Business Highlights</title>
<link>https://6ix.com/company/alto-neuroscience-inc/news/alto-neuroscience-reports-full-year-2025-financial-results-and-recent-business-highlights</link>
<guid isPermaLink="true">https://6ix.com/company/alto-neuroscience-inc/news/alto-neuroscience-reports-full-year-2025-financial-results-and-recent-business-highlights</guid>
<pubDate>Mon, 16 Mar 2026 10:03:00 GMT</pubDate>
<description>MOUNTAIN VIEW, Calif., March 16, 2026--Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today reported financial results for the full year ended December 31, 2025, and highlighted recent progress across its pipeline of clinical-stage product candidates.</description>
</item>
<item>
<title>Alto Neuroscience Announces Participation at the Stifel 2026 Virtual CNS Forum</title>
<link>https://6ix.com/company/alto-neuroscience-inc/news/alto-neuroscience-announces-participation-at-the-stifel-2026-virtual-cns-forum</link>
<guid isPermaLink="true">https://6ix.com/company/alto-neuroscience-inc/news/alto-neuroscience-announces-participation-at-the-stifel-2026-virtual-cns-forum</guid>
<pubDate>Fri, 13 Mar 2026 12:03:00 GMT</pubDate>
<description>MOUNTAIN VIEW, Calif., March 13, 2026--Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that members of the Company’s management team will participate in a virtual fireside chat at the Stifel 2026 Virtual CNS Forum on March 17, 2026 at 12:00pm ET.</description>
</item>
<item>
<title>Alto Neuroscience Announces Participation in Upcoming Investor Conferences</title>
<link>https://6ix.com/company/alto-neuroscience-inc/news/alto-neuroscience-announces-participation-in-upcoming-investor-conferences</link>
<guid isPermaLink="true">https://6ix.com/company/alto-neuroscience-inc/news/alto-neuroscience-announces-participation-in-upcoming-investor-conferences</guid>
<pubDate>Mon, 23 Feb 2026 13:33:00 GMT</pubDate>
<description>MOUNTAIN VIEW, Calif., February 23, 2026--Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that members of the Company’s management team will participate in the following upcoming investor conferences:</description>
</item>
<item>
<title>Alto Neuroscience Announces Completion of Enrollment in Phase 2 Proof-of-Concept Study of ALTO-101 in Cognitive Impairment Associated with Schizophrenia</title>
<link>https://6ix.com/company/alto-neuroscience-inc/news/alto-neuroscience-announces-completion-enrollment-130400380</link>
<guid isPermaLink="true">https://6ix.com/company/alto-neuroscience-inc/news/alto-neuroscience-announces-completion-enrollment-130400380</guid>
<pubDate>Fri, 13 Feb 2026 13:04:00 GMT</pubDate>
<description>MOUNTAIN VIEW, Calif., February 13, 2026--Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced the completion of patient enrollment in its Phase 2 proof-of-concept clinical trial evaluating ALTO-101, a novel, transdermal phosphodiesterase-4 (PDE4) inhibitor, for the treatment of cognitive impairment associated with schizophrenia (CIAS). Topline data from th</description>
</item>
<item>
<title>Alto Neuroscience Highlights Invited Review in American Journal of Psychiatry Establishing Neuroplasticity as a Core Driver of Psychiatric Disease and Treatment</title>
<link>https://6ix.com/company/alto-neuroscience-inc/news/alto-neuroscience-highlights-invited-review-132700199</link>
<guid isPermaLink="true">https://6ix.com/company/alto-neuroscience-inc/news/alto-neuroscience-highlights-invited-review-132700199</guid>
<pubDate>Tue, 03 Feb 2026 13:27:00 GMT</pubDate>
<description>MOUNTAIN VIEW, Calif., February 03, 2026--Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced the publication of a review, "Brain Neuroplasticity Mechanisms in Psychiatric Illnesses and in the Development of Novel Treatments," in the American Journal of Psychiatry. The review was co-authored by members of Alto Neuroscience’s leadership team, Patricio O’Don</description>
</item>
<item>
<title>Alto Neuroscience Strengthens Intellectual Property Portfolio with Issuance of New Method-of-Treatment Patent for ALTO-207 in Depression</title>
<link>https://6ix.com/company/alto-neuroscience-inc/news/alto-neuroscience-strengthens-intellectual-property-122700975</link>
<guid isPermaLink="true">https://6ix.com/company/alto-neuroscience-inc/news/alto-neuroscience-strengthens-intellectual-property-122700975</guid>
<pubDate>Wed, 14 Jan 2026 12:27:00 GMT</pubDate>
<description>MOUNTAIN VIEW, Calif., January 14, 2026--Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced the issuance of U.S. Patent Number 12,521,374 covering methods of treating depression with ALTO-207, a novel combination of pramipexole and ondansetron. The patent protects a key aspect of ALTO-207 – the use of ondansetron to mitigate pramipexole-related side effec</description>
</item>
<item>
<title>Alto Neuroscience Presents New Data at the 64th Annual Meeting of the American College of Neuropsychopharmacology</title>
<link>https://6ix.com/company/alto-neuroscience-inc/news/alto-neuroscience-presents-data-64th-130000019</link>
<guid isPermaLink="true">https://6ix.com/company/alto-neuroscience-inc/news/alto-neuroscience-presents-data-64th-130000019</guid>
<pubDate>Tue, 13 Jan 2026 13:00:00 GMT</pubDate>
<description>MOUNTAIN VIEW, Calif., January 13, 2026--Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced multiple presentations highlighting new data and analyses supporting the Company’s development programs at the 64th annual meeting of the American College of Neuropsychopharmacology (ACNP) held January 12-15, 2026.</description>
</item>
<item>
<title>Alto Neuroscience Announces New Employee Inducement Grants Under NYSE Rule 303A.08</title>
<link>https://6ix.com/company/alto-neuroscience-inc/news/alto-neuroscience-announces-employee-inducement-210500366</link>
<guid isPermaLink="true">https://6ix.com/company/alto-neuroscience-inc/news/alto-neuroscience-announces-employee-inducement-210500366</guid>
<pubDate>Wed, 03 Dec 2025 21:05:00 GMT</pubDate>
<description>MOUNTAIN VIEW, Calif., December 03, 2025--Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that on December 2, 2025, the Compensation and Management Development Committee of Alto’s Board of Directors granted a new employee an option to purchase 150,000 shares of Alto’s common stock. The stock option was granted under Alto’s 2025 Inducement Plan as a mat</description>
</item>
<item>
<title>Alto Neuroscience Reports Third Quarter 2025 Financial Results and Recent Business Highlights</title>
<link>https://6ix.com/company/alto-neuroscience-inc/news/alto-neuroscience-reports-third-quarter-125700932</link>
<guid isPermaLink="true">https://6ix.com/company/alto-neuroscience-inc/news/alto-neuroscience-reports-third-quarter-125700932</guid>
<pubDate>Wed, 12 Nov 2025 12:57:00 GMT</pubDate>
<description>MOUNTAIN VIEW, Calif., November 12, 2025--Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today reported financial results for the quarter ended September 30, 2025, and highlighted recent progress across its pipeline of clinical-stage product candidates.</description>
</item>
<item>
<title>Alto Neuroscience to Participate in Upcoming Investor Conferences</title>
<link>https://6ix.com/company/alto-neuroscience-inc/news/alto-neuroscience-participate-upcoming-investor-113400832</link>
<guid isPermaLink="true">https://6ix.com/company/alto-neuroscience-inc/news/alto-neuroscience-participate-upcoming-investor-113400832</guid>
<pubDate>Tue, 28 Oct 2025 11:34:00 GMT</pubDate>
<description>MOUNTAIN VIEW, Calif., October 28, 2025--Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that members of the Company’s management team will present at the following upcoming investor conferences:</description>
</item>
<item>
<title>Alto Neuroscience Announces $50 Million Private Placement Financing</title>
<link>https://6ix.com/company/alto-neuroscience-inc/news/alto-neuroscience-announces-50-million-110300544</link>
<guid isPermaLink="true">https://6ix.com/company/alto-neuroscience-inc/news/alto-neuroscience-announces-50-million-110300544</guid>
<pubDate>Mon, 20 Oct 2025 11:03:00 GMT</pubDate>
<description>MOUNTAIN VIEW, Calif., October 20, 2025--Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, announced today that it has entered into a securities purchase agreement with institutional and accredited investors to sell securities in a private placement financing (the "PIPE") for gross proceeds of approximately $50 million, before deducting offering expenses. The financing</description>
</item>
<item>
<title>Alto Neuroscience Announces Plans to Accelerate Development of ALTO-207 in Treatment Resistant Depression Following Successful Outcome from Recent FDA Meeting</title>
<link>https://6ix.com/company/alto-neuroscience-inc/news/alto-neuroscience-announces-plans-accelerate-110100734</link>
<guid isPermaLink="true">https://6ix.com/company/alto-neuroscience-inc/news/alto-neuroscience-announces-plans-accelerate-110100734</guid>
<pubDate>Mon, 20 Oct 2025 11:01:00 GMT</pubDate>
<description>MOUNTAIN VIEW, Calif., October 20, 2025--Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, announced today that, following a successful outcome from a recent FDA meeting, it plans to accelerate the development of ALTO-207 for people with treatment resistant depression (TRD). The $50 million private placement announced today supports expanded development of ALTO-207, and</description>
</item>
<item>
<title>Alto Neuroscience Receives FDA Fast Track Designation for ALTO-101 for the Treatment of Cognitive Impairment Associated with Schizophrenia</title>
<link>https://6ix.com/company/alto-neuroscience-inc/news/alto-neuroscience-receives-fda-fast-113400725</link>
<guid isPermaLink="true">https://6ix.com/company/alto-neuroscience-inc/news/alto-neuroscience-receives-fda-fast-113400725</guid>
<pubDate>Fri, 03 Oct 2025 11:34:00 GMT</pubDate>
<description>MOUNTAIN VIEW, Calif., October 03, 2025--Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ALTO-101 for the treatment of cognitive impairment associated with schizophrenia (CIAS). There are currently no approved treatments for CIAS, a core feature of schizophrenia that</description>
</item>
<item>
<title>Alto Neuroscience Announces Robust Replication of EEG Biomarker to Objectively Identify Patients with Cognitive Impairment in Schizophrenia</title>
<link>https://6ix.com/company/alto-neuroscience-inc/news/alto-neuroscience-announces-robust-replication-110900071</link>
<guid isPermaLink="true">https://6ix.com/company/alto-neuroscience-inc/news/alto-neuroscience-announces-robust-replication-110900071</guid>
<pubDate>Tue, 09 Sep 2025 11:09:00 GMT</pubDate>
<description>MOUNTAIN VIEW, Calif., September 09, 2025--Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced positive results from an independent, prospective replication study evaluating electroencephalography (EEG) biomarkers in people with schizophrenia. The study successfully replicated previous findings, demonstrating that event-related theta-band responses, particu</description>
</item>
<item>
<title>Alto Neuroscience Reports Second Quarter 2025 Financial Results and Recent Business Highlights</title>
<link>https://6ix.com/company/alto-neuroscience-inc/news/alto-neuroscience-reports-second-quarter-201000890</link>
<guid isPermaLink="true">https://6ix.com/company/alto-neuroscience-inc/news/alto-neuroscience-reports-second-quarter-201000890</guid>
<pubDate>Wed, 13 Aug 2025 20:10:00 GMT</pubDate>
<description>MOUNTAIN VIEW, Calif., August 13, 2025--Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today reported financial results for the quarter ended June 30, 2025, and highlighted recent progress across its pipeline of clinical-stage product candidates.</description>
</item>
</channel>
</rss>